Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11728789 | 1.00 | CYP1A2 (0.46) | CYP1A2MAPK1SMN1; SMN2HRH3 | |
| SCHEMBL18939490 | 0.94 | HRH3 (0.43) | CYP1A2MAPK1SMN1; SMN2HRH3 | |
| SCHEMBL27778767 | 0.93 | TSHR (0.43) | HRH3 | |
| Hydrochloric Acid SCHEMBL7326371 | 0.86 | HRH3 (0.40) | HRH3 | |
| SCHEMBL23828674 | 0.79 | HRH3 (0.44) | HRH3 | |
| SCHEMBL1861972 | 0.78 | HRH3 (0.62) | CYP1A2MAPK1SMN1; SMN2HRH3 | |
| SCHEMBL1856917 | 0.78 | HRH3 (0.62) | CYP1A2MAPK1SMN1; SMN2HRH3 | |
| SCHEMBL1858200 | 0.78 | HRH3 (0.62) | CYP1A2MAPK1SMN1; SMN2HRH3 | |
| SCHEMBL11615000 | 0.77 | L3MBTL1 (0.50) | — | |
| SCHEMBL11615002 | 0.77 | L3MBTL1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679287-B | Nicotinic acetylcholine receptor modulators | SIENA BIOTECH SPA | 2013-03-27 | — | — | CN | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2323988-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| CN-101679287-A | nicotinic acetylcholine receptor modulators | SIENA BIOTECH SPA | 2010-03-24 | — | — | CN | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| US-4898871-A | Pyrrole derivatives and pharmaceutical compositions which contain them as hypnotics and anticonvulsants | RHONE-POULENC SANTE (FR) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | CYP1A2 1261/4885MAPK1 1781/4885SMN1; SMN2 2002/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | CYP1A2 2584/4885MAPK1 1513/4885SMN1; SMN2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.